Key Highlights

  • Perrigo closed up 23.10% at $13.27 on August 5, extending a rally that began after Tuesday's earnings report.
  • Second-quarter adjusted EPS of $0.50 beat the $0.34 consensus estimate, with net sales of $1.02 billion topping expectations despite a 3.2% year-over-year decline.
  • Infant Formula sales grew 23%, and Oral Care sales also topped expectations, offsetting category softness elsewhere in the portfolio.
  • Management reaffirmed full-year 2026 guidance for adjusted EPS of $2.00 to $2.30.
  • The strategic review process is ongoing after the company disclosed it has received an unsolicited acquisition proposal and multiple expressions of interest, with an independent board committee advised by Evercore evaluating options.

What Happened

Perrigo (NYSE:PRGO) is a Dublin, Ireland-headquartered consumer self-care company founded in 1887, recognized as the largest store-brand over-the-counter provider in the United States and a top 10 OTC company in Europe. Operating through its Consumer Self-Care Americas and Consumer Self-Care International segments, the company develops, manufactures, and markets a broad portfolio of private-label and branded OTC health and wellness products, including brands such as Mederma, Compeed, Opill, Nasonex, ellaOne, and Prevacid24HR.

Shares surged after the company reported second-quarter adjusted EPS of $0.50, sharply beating the $0.34 consensus estimate, while net sales of $1.02 billion also topped expectations despite a 3.2% year-over-year decline. Investors responded positively to continued progress on the company's strategic review, alongside ongoing reviews of Infant Formula and Oral Care outlook, which management reaffirmed for full-year 2026 adjusted EPS of $2.00 to $2.30.

Strategic Review and Unsolicited Proposal

The company disclosed a strategic review process after receiving an unsolicited acquisition proposal and multiple expressions of interest, with an independent board committee, advised by Evercore, evaluating options including a potential sale or standalone path. The stock's sharp rally today also reflects relief after shares had fallen roughly 22% year-to-date amid category softness and macroeconomic headwinds, with the beat-and-raise signaling stabilization and a stronger anticipated second half.

Market gains included U.S. store brand OTC volumes up 1.9% in self-care and specialty care, and Oral Care volumes up 6.9% year-over-year, with the retailer relationship positive for the fourth consecutive quarter. Growth drivers included Infant Formula and Oral Care outperformance, continued progress on strategic optimizer, product mix, and lower interest expense; full-year effective tax rate estimate lowered to 20% to 18%, and diluted shares outstanding updated to 139.3 million.

Operational Enhancement Progress

The company reiterated its Operational Enhancement program remains on track to deliver $80 million to $100 million in savings by 2027, and full-year invention pipeline levels have more than tripled since 2024, with 55% of projects leveraging shared platforms. The company ended the second quarter with $400 million cash and $3.3 billion total debt.

Conclusion

Perrigo's sharp rally on August 5 reflects investor relief that the earnings beat and reaffirmed guidance signal stabilization following a difficult year-to-date stretch, while the ongoing strategic review process adds an additional layer of speculative interest to the stock. With Infant Formula and Oral Care both outperforming expectations, today's close suggests renewed confidence that the company's turnaround efforts are gaining traction.

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.